Will FDA Move BPC-157 to Category 1 by August 2026?

The FDA scheduled a two-day Pharmacy Compounding Advisory Committee hearing for July 23 and 24, 2026, and BPC-157 is on the agenda. That hearing is the single gate between this peptide and Category 1 status. The prediction market puts the August 31 outcome at 43.5%, a number that fell sharply on June 29 and signals real doubt about the timeline.

The market question asks whether the FDA moves BPC-157 to Category 1 by August 31, 2026. YES trades at $0.44 and NO trades at $0.57, with $780 in total volume as of June 29, 2026. The market closes December 31, 2026, leaving the December date as the alternative resolution window.

How the BPC-157 Contract Works

A YES resolution requires the FDA to formally grant BPC-157 Category 1 compounding status, meaning inclusion on the 503A Bulk Drug Substances List, on or before August 31, 2026. The Pharmacy Compounding Advisory Committee makes a recommendation at the July hearing; the FDA then acts on that recommendation. A NO resolution on August 31 does not end the market. It shifts resolution to December 31, 2026.

• YES ($0.44, implied 43.5%): FDA completes Category 1 reclassification by August 31, 2026.
• NO ($0.57, implied 56.5%): FDA does not complete reclassification by August 31, 2026.

BPC-157 stays out of Category 1 by August 31 if the PCAC issues a negative recommendation on July 23 or 24, or if the FDA delays its formal decision beyond the August deadline. Regulatory bodies routinely take weeks to act after an advisory committee vote. Even a favorable hearing outcome may not produce a written determination before August 31.

Sponsored Partner

Market Signals: A Sharp Drop With No Obvious Floor

The momentum composite here is striking. The 1-hour change sits at 0.0%, the 24-hour change is down 16.5%, and the trend score is 16.59. That combination tells one story: the market dropped hard on June 29 and has not found a stabilizing bid. A trend score above 15 during a steep single-session decline means selling pressure, not a brief dip. The June 29 drop is the dominant signal.

Total volume is $780, with all $780 trading in the past 24 hours. Liquidity stands at $682. This is a thin, reactive market. A single informed trader moving a few hundred dollars drives price. Volume this low means the 16.5% daily drop reflects a real conviction shift, not noise from a deep book.

• BPC-157 dropped 16.5% on June 29, 2026, with the trend score at 16.59, indicating concentrated selling pressure rather than gradual repositioning.
• The 1-hour change of 0.0% after a 16.5% daily fall shows the market absorbed the shock but has not recovered.
• Total volume of $780 and liquidity of $682 confirm this is a low-depth market where individual trades move prices significantly.
• The July 23 and 24 PCAC hearing is the single near-term catalyst. All price movement before that date is speculative positioning.
• NO holds at $0.57, reflecting the majority view that the August 31 deadline is too tight for full regulatory action even after a favorable committee vote.

Lines Analysis: Why the August Deadline Is the Real Question

The math here does not favor the August 31 date on procedural grounds alone. The PCAC hears BPC-157 on July 23 or 24. Even if the committee recommends Category 1 inclusion, the FDA must then draft, review, and publish a formal determination. That process typically takes weeks. Fitting a full regulatory action between a late-July hearing and an August 31 deadline is genuinely difficult. The 43.5% YES price reflects that compression, not pessimism about the underlying substance.

The December 31 alternative gives the market a second resolution window. If the August gate closes, traders who hold NO on August 31 are betting that the FDA also fails to act by year-end. That is a separate and harder argument. The NO side wins on August 31 if the FDA moves slowly after the July hearing, which is the base-rate expectation for a federal regulatory body managing seven peptides simultaneously at the same hearing.

• A favorable PCAC recommendation on July 23 or 24 would push YES sharply higher heading into the August deadline.
• A negative PCAC recommendation collapses the YES price and strengthens NO for both the August and December windows.
• Any FDA signal of expedited action after the July hearing narrows the procedural gap and lifts YES back toward or above $0.55.
• A second peptide on the July agenda receiving a negative ruling would dampen overall sentiment for BPC-157 even before the committee reaches it.
• Regulatory delay without a negative recommendation keeps the December window open and maintains moderate YES value for that outcome.

Total volume of $780 makes this a low-conviction market. The data currently favors NO on the August 31 deadline, driven by procedural timeline risk rather than any negative signal about the substance itself. The July 23 hearing changes everything.

LINES VERDICT

August Deadline Unlikely, December Still Live

The July 23 PCAC hearing is the pivot point, but federal regulatory timelines rarely accommodate a late-July vote and an August 31 written determination. The procedural math favors NO on the August outcome.

What the market says: At 43.5%, the market sees the August 31 deadline as a coin-flip leaning against YES. This probability is volatile heading into the July 23 hearing date, and any PCAC recommendation will reprice this market immediately.